Offer - Urjas Oil for just ₹ 1 X
Nevimune Tablet (60) is a prescription drug, available for use as Tablet. It is typically used for the treatment of HIV/AIDS.
The optimal dosage of Nevimune Tablet (60) is largely dependent on the individual's body weight, medical history, gender and age. Besides the medical condition it is advised for, the route of administration also plays an important role in determining the correct drug dosage. For detailed information on this, read through the dosage section.
Apart from the aforementioned side effects, Nevimune Tablet (60) can also lead to other problems, which have been listed below. These side effects of Nevimune Tablet (60) are usually temporary and subside with the completion of treatment. However, if these continue for a longer time, consult your doctor right away.
It is also important to note that Nevimune Tablet (60) has a Safe effect for pregnant women and Safe effect on lactating mothers. Warnings related to Nevimune Tablet (60)'s effects on the liver, heart and kidney, if any, have been listed below.
Nevimune Tablet (60) can cause adverse effects in certain medical conditions. It is strongly recommended to avoid Nevimune Tablet (60) in conditions like Liver Disease. Other contraindications of Nevimune Tablet (60) have been discussed in the sections ahead.
Drug interactions for Nevimune Tablet (60) have been reported in the medical literature. Refer to the list below for further details.
Along with the above-mentioned precautions, remember that taking Nevimune Tablet (60) is considered not safe while driving, and is not addictive.
Nevimune Tablet (60) is used to treat the following -
Other Benefits
This is the usual dosage recommended in most common treatment cases. Please remember that every patient and their case is different, so the dosage can be different based on the disease, route of administration, patient's age and medical history.
Find the right dosage based on disease and age
Age Group | Dosage |
Adult |
|
Geriatric |
|
Neonates (0 to 1 month) |
|
Infant (1 month to 2 years) |
|
2 - 12 years (Child) |
|
13 - 18 years (Adolescent) |
|
Is the use of Nevimune Tablet (60) safe for pregnant women?
Pregnant women can take Nevimune safely.
Is the use of Nevimune Tablet (60) safe during breastfeeding?
Nevimune does not show any side effects in breastfeeding women.
What is the effect of Nevimune Tablet (60) on the Kidneys?
Using Nevimune does not have any harmful effects on kidneys.
What is the effect of Nevimune Tablet (60) on the Liver?
Side effects of Nevimune rarely affect the liver.
What is the effect of Nevimune Tablet (60) on the Heart?
Nevimune is completely safe for the heart.
Nevimune Tablet (60) should not be taken with following medicines due to severe side effects it may cause to patients -
Severe
Moderate
Mild
If you are suffering from any of the following diseases, you should not take Nevimune Tablet (60) unless your doctor advises you to do so -
Is this Nevimune Tablet (60) habit forming or addictive?
No, you will not get addicted to Nevimune Tablet (60).
Is it safe to drive or operate heavy machinery when consuming?
After taking Nevimune Tablet (60), you should not drive or work on any heavy machine, as Nevimune Tablet (60) can make you drowsy.
Is it safe?
Nevimune Tablet (60) is safe but it is important to consult a doctor before taking it.
Is it able to treat mental disorders?
Nevimune Tablet (60) is unable to treat or cure mental disorders.
Interaction between Food and Nevimune Tablet (60)
Taking Nevimune Tablet (60) with food does not cause any problems.
Interaction between Alcohol and Nevimune Tablet (60)
No research has been done on this till date. Therefore, it is not known what the effect of taking Nevimune Tablet (60) with alcohol will be.
This medicine data has been created by -
B.Pharma, Pharmacy
5 Years of Experience
References
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Viramune® (nevirapine)
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 809